BioSpace News Archive

Vir Biotechnology, Inc. announced it ranked first for the second year in a row on the 2023 Deloitte Technology Fast 500™, a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America.

Biological Dynamics, Inc. announced the first opportunity for external users to access the company’s ExoVerita Pro, a cost-efficient, automated exosomal enrichment platform that delivers samples with best-in-class yields, purity, and reproducibility.

Yield10 Bioscience, Inc. today announced that the Company will report its third quarter 2023 financial results and provide a corporate update on Tuesday, November 14, 2023.

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, announced its third quarter 2023 financial results and provided a business update.

Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system, provided a corporate update and announced preliminary and unaudited financial results for the third quarter ended September 30, 2023.

Sera Prognostics Inc., The Pregnancy Company®, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced financial results for the third quarter of 2023 ended September 30, 2023.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company’s senior management team will participate in the following investor conferences in November.

Azenta, Inc. will announce fiscal fourth quarter and full year 2023 earnings which ended on September 30, 2023 on Monday, November 13, 2023 after the market closes.

REGENXBIO Inc. announced financial results for the third quarter ended September 30, 2023, and recent operational highlights, including a strategic pipeline prioritization and corporate restructuring intended to significantly reduce operating expenses while continuing to support meaningful value generation from the Company’s strong pipeline of AAV Therapeutics.

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate in a fireside chat at the Jefferies London Healthcare Conference on November 15, 2023 at 12:00pm GMT/7:00am EST.